Pfizer beats Q2 estimates with rising oncology sales, new drug launches, and strong Seagen-driven portfolio growth.

You'll recognize the maker of this drug, which treats an issue affecting a larger percentage of the population than many ...

Pfizer › Pfizer (NYSE: PFE) has been a terrible investment over the past three years. Revenue and earnings have generally ...

Pfizer CEO Albert Bourla is expected at a pro-Trump fundraiser on Friday, sources told CBS News, one day after the president ...

Pfizer PFE is due to report second-quarter results on Aug. 5. All eyes will be on sales of Pfizer’s oncology drugs, which account for around 25% of the company’s total revenues. Pfizer’s key oncology ...

Those who invested in Pfizer three years ago and hung on are not thrilled. They would have done much better with a simple S&P ...

Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

One relatively safe bet about how Pfizer's lineup will look different five years from now is that the company will be a ...

Pfizer Inc.’s stock was rallying Tuesday after the drug giant lifted its 2025 adjusted profit estimate, on the heels of a 10% ...

2 Companies Poised to Capitalize on the Rise of GLP-1 Drugs Move over, Novo Nordisk and Eli Lilly. Why Pfizer and Roche look like top choices for investors. Pandora Zilstorff Jan 21, 2025 ...